Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ulimorelin in Healthy Subjects
NCT02993055Phase 1Completed
- Sponsor
- Lyric Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules, Cyclic Peptides
01
Overview
Phase 1, randomised, double-blind trial in gastroparesis comparing Ulimorelin with Placebo (2 arms). Primary endpoint: Maximum Plasma Concentration at 7 days. Started Jan 2015; status: completed.
02
Drugs
ulimorelin
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT02993055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993055.